Episode Details

Back to Episodes
Vaping Cessation: Achieve Life Sciences Announces Positive Phase 2 ORCA--V1 Trial Results | Pharmacy Podcast Nation

Vaping Cessation: Achieve Life Sciences Announces Positive Phase 2 ORCA--V1 Trial Results | Pharmacy Podcast Nation

Episode 1608 Published 2 years, 7 months ago
Description

An estimated 28.3 million adults in the United States currently smoke cigarettes. 
More than 16 million Americans live with a smoking-related disease. 1 in 20 Americans vape, and teenage e-cigarette consumption has increased by 1,800% over the last year. 14.1% (2.14 million) of high school students and 3.3% (380,000) of middle school students reported current e-cigarette use.

John Bencich is the CEO of Achieve Life Sciences.  Achieve Life Sciences, Inc. a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, reported positive topline results from its Phase 2 ORCA-V1 trial. ORCA-V1 evaluated the efficacy and safety of 3mg cytisinicline dosed three times daily for 12 weeks compared to placebo in 160 adults who use e-cigarettes or nicotine vapes and who do not currently smoke cigarettes. All participants received behavioral support for nicotine cessation.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us